<DOC>
	<DOCNO>NCT02305901</DOCNO>
	<brief_summary>To assess influence BI 187004 pharmacokinetics CYP2C8 CYP2B6 probe drug repaglinide bupropion mean predict drug-drug interaction .</brief_summary>
	<brief_title>The Effect Multiple Doses BI 187004 Single-dose Pharmacokinetics Repaglinide Bupropion Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<criteria>Inclusion criterion : 1 . Healthy male subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test 2 . Age 18 55 year ( incl . ) 3 . Body mass index ( BMI ) 18.5 29.9 kg/m2 ( incl . ) 4 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator 2 . Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 bpm 3 . Any laboratory value outside reference range investigator considers clinical relevance 4 . Any evidence concomitant disease judge clinically relevant investigator 5 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 6 . Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) 7 . Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder Further exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>